Regenerative Therapies Library
Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 49–72 of 297
Antioxidants eliminate senescent muscle cells via redox targeting
Senescent muscle precursor cells depend on ROS-driven Akt/mTORC1 signaling to maintain their dysfunctional state. Antioxidant treatment can suppress this pathway, reduce inflammatory output, and selectively eliminate senescent cells while sparing healthy muscle precursors—a mechanism relevant to cellular senescence reversal strategies in aging muscle.
Senescent Microglia Drive Brain Aging—Reversible via Senotherapeutics
Senescent microglia accumulate in aging brains and drive neuroinflammation; targeted senotherapeutic interventions suppress this state and restore microglial function. This represents a mechanistic pathway to reduce age-related cognitive decline through cellular state modification rather than broad immunosuppression.
Precision targeting of the SASP in cancer therapy
TGFβ signaling emerges as the primary tumor-promoting mechanism within senescent cells induced by platinum chemotherapy in ovarian and lung cancers. Targeting this pathway selectively could preserve the therapeutic benefit of chemotherapy while blocking its pro-tumor effects, addressing a critical vulnerability in current cancer treatment.
How a Growth Factor and SIRT1 Might Combat Disc Degeneration
FGF21, a growth factor that declines with age, delays intervertebral disc degeneration by upregulating SIRT1 and restoring mitochondrial quality control through the PINK1-Parkin mitophagy pathway. This mechanism addresses a primary driver of age-related lower back pain by counteracting cellular senescence in disc tissue.
Cell cycle inhibitors suppress senescent inflammation
CDK4/6 inhibitors reduce senescence-associated inflammation by disrupting a signaling pathway that links cell cycle control to NF-κB activation, improving physical function in aging and chemotherapy recovery. This identifies a mechanistic bridge between cellular aging and inflammatory dysfunction that may be pharmacologically addressable.
Plug-and-play peptides hit longevity and wellness market
LifespanningRx has launched a plug-and-play platform enabling wellness businesses to offer peptide therapy within 24 hours without inventory management, regulatory overhead, or upfront investment. This model addresses the growing demand for personalized longevity interventions by removing operational barriers and shifting competition from the therapies themselves to seamless delivery infrastructure.
Immortal Dragons backs 3D biofabrication to tackle organ failure
Immortal Dragons is directing capital toward 3D biofabrication technologies that use living cells and biocompatible materials to engineer functional tissues and vascular structures. This represents a strategic shift in longevity investment toward regenerative approaches that intervene before organ failure becomes clinically symptomatic.
Mesoblast invests in smarter cell therapies with new CAR tech deal
Mesoblast has licensed CAR technology to enhance its mesenchymal stromal cell therapies, enabling more precise targeting of inflamed tissues in autoimmune and inflammatory conditions. This represents a shift from broad biological effects to engineered precision at the cellular level, potentially improving both efficacy and speed of response in diseases like inflammatory bowel disease and lupus nephritis.
Overactivation of Cdc42 GTPase Impairs the Cytotoxic Function of NK Cells From Old Individuals Towards Senescent Fibroblasts
Natural killer cells from older adults fail to clear senescent fibroblasts due to overactivation of the Cdc42 protein, which disrupts the cellular machinery required for releasing cytotoxic granules and producing ATP. Pharmacological inhibition of Cdc42 restores this clearing capacity and offers a potential therapeutic target for age-related disease driven by senescent cell accumulation.
Preserve Your Younger Cells Before Age Damages Them
Preserving stem cells harvested from hair follicles during younger years creates a biological reservoir of undamaged cells available for future regenerative therapies. This approach shifts longevity strategy from reactive treatment of age-related decline to proactive preservation of cellular potential before damage accumulates.
Telomir Pharmaceuticals reports new data on epigenetic modulation mechanism
Telomir-1 (Telomir-Zn) modulates intracellular metal balance by increasing zinc and reducing iron, influencing epigenetic regulation and cellular stability without triggering cytotoxic stress. This mechanism addresses oxidative stress and genomic integrity pathways implicated in aging and cancer biology.
Protein Restriction Activates FGF21 Longevity Pathway
Moderate protein restriction activates fibroblast growth factor 21 (FGF21), improving metabolic efficiency and extending lifespan in animal models. This challenges prevailing high-protein recommendations for sedentary populations and suggests protein quantity requires context-specific calibration based on activity level and metabolic state.
The shift from stem cells to signals
Clinical evidence shows transplanted stem cells often fail to survive beyond days, yet patients continue improving—suggesting the therapeutic mechanism resides in transient molecular signals rather than cell persistence. This shift from cellular replacement to signal-based regenerative therapy reframes aging as a coordination failure rather than a structural deficit, with profound implications for scalable longevity medicine.
Catheter-Delivered Stem Cells Restore Cardiac Function
Heartseed has dosed the first patient in a Phase I/II trial of HS-005, an iPSC-derived cardiomyocyte therapy delivered by catheter to treat severe heart failure. This represents the first clinical administration of stem cell-derived cardiac muscle cells via endocardial catheter, establishing a minimally invasive alternative to open-heart surgical approaches for myocardial regeneration.
Stem cell cardiomyocytes restore dilated heart function
Heartseed initiated dosing in a Phase I/II trial of HS-005, an allogeneic stem cell-derived cardiomyocyte therapy for dilated cardiomyopathy delivered via catheter. Early safety data from the first patient supported trial continuation, positioning cell therapy as a potential intervention for non-ischemic heart failure.
PranaX lands $17m to harness exosomes in regenerative biologics
PranaX secured $17 million in Series A funding to develop exosome-based therapeutics licensed from UT MD Anderson, targeting age-related inflammation and tissue degeneration. The company plans to commercialize stem cell-derived exosome products for wellness applications and potentially clinical programs addressing chronic age-related conditions.
Cell therapies achieve durable regeneration without immunosuppression
Sana Biotechnology is advancing multiple cell and gene therapy candidates toward clinical trials in 2026-2027, with SC451 expected to enter Phase 1/2 trials as early as 2026 and preclinical data demonstrating targeted cell delivery without chemotherapy depletion. The company's $160.5 million cash position and strategic partnerships position it to pursue regenerative approaches for conditions ranging from autoimmune disease to type 1 diabetes.
Umbilical Exosomes Restore Liver Autophagy in Aging
Exosomes derived from human umbilical cord mesenchymal stem cells reverse age-related liver dysfunction and fatty infiltration in aging mice by restoring autophagy and reducing cellular senescence markers. This demonstrates a potential approach to address metabolic liver disease through enhancement of the body's intrinsic cellular maintenance systems.
Periodic Therapeutic Phlebotomy Mitigates Systemic Aging Phenotypes by Promoting Bone Marrow Function
Periodic therapeutic phlebotomy restores bone marrow function in aging models, reducing senescence markers and improving tissue integrity across multiple organ systems. The mechanism involves rebalancing hematopoietic homeostasis through rescue of mesenchymal and endothelial stem cells, suggesting a practical intervention with clinical translation potential.
Secretome Profiling of Young Multipotent Stem Cells Reveals Angiogenic and Immunomodulatory Mechanisms Supporting Aged Neuromuscular Health
Young muscle-derived stem cells secrete pro-angiogenic and immunomodulatory proteins that decline with age. Systemic transplantation of these young cells into aged mice restored neuromuscular structure and function through paracrine signaling, with effects sustained for two months.
Plasma Dilution After Myocardial Ischemia–Reperfusion Injury Promotes Cardiac Repair, Heart Performance, and Recovery of Motor Function and Endurance in Old Mice
Plasma dilution performed 24 hours after myocardial ischemia–reperfusion injury in aged mice significantly improved cardiac function, reduced fibrosis and inflammation, and restored physical performance through enhanced cellular repair and modified inflammatory signaling pathways. This finding addresses a critical gap in aging-relevant cardiac research by demonstrating that manipulating the blood's humoral environment after acute injury can shift the trajectory of tissue recovery in older organisms.
AGGF1 Decline Drives Age-Related Hypertension Through Mitochondrial Dysfunction
AGGF1, an endothelial protein that declines with age, regulates blood pressure through a signaling pathway that controls mitochondrial function and nitric oxide production. Loss of AGGF1 accelerates vascular aging and elevates blood pressure in male mice, while restoring AGGF1 expression reverses these changes, identifying a potential intervention target for age-related hypertension.
Immune Cell Aging Drives Atherosclerosis via Telomerase Loss
A correction to prior research clarifies the role of telomerase in myeloid cell function and atherosclerosis progression. The findings demonstrate that telomerase loss in immune cells accelerates dyslipidemia, foam cell accumulation, and downstream organ damage—connecting immune cell aging to systemic cardiovascular and pulmonary pathology.
Pulmatrix and Eos merge to advance gerotherapeutics
Pulmatrix and Eos SENOLYTIX are merging to develop PTC-2105, a candidate designed to modulate mitochondrial function and clear senescent cells in sarcopenia and metabolic disease. The transaction signals a fundamental shift in biopharma toward targeting aging biology directly rather than its downstream manifestations.